A Phase II Study of Oral Once Daily GW572016 (Lapatinib) In Patients With Hormone Refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Lapatinib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms NRR
- 31 Aug 2018 Biomarkers information updated
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2012 Actual patient number is 35 according to ClinicalTrials.gov.